Oxygen Biotherapeutics Inc.

EANS-Adhoc: Oxygen Biotherapeutics to Voluntarily Withdraw Secondary Listing from SIX Swiss Stock Exchange


--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
28.10.2011

MORRISVILLE, NC, October 27, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX:
OXBT) today announced that the SIX Swiss Stock Exchange has approved the
application filed by the company on September 30, 2011, to remove the company's
shares from trading on the SIX exchange. This application was filed after the
Company's Board of Directors determined that the cost of maintaining the SIX
listing was not justified in light of the low trading volume of the Company's
shares over the past 12 months.  The last day of trading for the company's
common stock on the SIX will be January 30, 2012. 

Shares will continue to trade on the NASDAQ OMX under the symbol OXBT.

end of ad-hoc-announcement
================================================================================
About Oxygen Biotherapeutics, Inc. 

Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing
medical and cosmetic products that efficiently deliver oxygen to tissues in the
body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier product called Oxycyte® that is being formulated for both
intravenous and topical delivery. The company has commercialized its DERMACYTE®
line of oxygen-rich skin care products. In addition, the company is focused on
PFC-based oxygen carriers for use in traumatic brain injury, decompression
sickness, and topical wound healing.  See www.oxybiomed.com for more
information. 

Caution Regarding Forward-Looking Statements 

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. These statements include the management transition,
and expansion of research and development of the Oxycyte product line, including
the timing of the introduction of these new products. The forward-looking
statements are subject to a number of risks and uncertainties including matters
beyond the company’s control that could lead to delays in new product
introductions and customer acceptance of these new products, and other risks and
uncertainties as described in our filings with the Securities and Exchange
Commission, including in the current annual report on Form 10-K filed on July
15, 2011 and current quarterly report on Form 10-Q filed on September 19, 2011.
The company disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. 



Further inquiry note:
Ellen Corliss	
Vice President, Corporate Communications 	
& Investor Relations			
Oxygen Biotherapeutics, Inc	
One Copley Pkwy, Suite 490	
Morrisville, NC 27560		
Direct Telephone: +1 919 855 2112			
Direct Fax: +1 919 806 4417	
Email: e.corliss@oxybiomed.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      Oxygen Biotherapeutics Inc.
             One Copley Parkway, Suite 490 
             US-27560 Morrisville, NC
phone:       +1 (919) 855 21 12
FAX:         +1 (919) 806 44 17
mail:     e.corliss@oxybiomed.com
WWW:      www.oxybiomed.com
sector:      Biotechnology
ISIN:        US69207P2092
indexes:     SSIRT
stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange 
language:   English
 

 

 



Das könnte Sie auch interessieren: